Alzheimer’s Disease: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve memory and daily activities in patients with mild cognitive impairment and Alzheimer's disease. This study will also assess its effects on brain health and quality of life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dimethyl Fumarate
Dimethyl fumarate is a substance that calms the immune system to help prevent relapses in multiple sclerosis and treat psoriasis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W Lodzi
Klinika Psychiatrii Wieku Podeszłego i Zaburzeń Psychotycznych
Łódź, Poland
Medical University Of Silesia Katowice Poland
Klinika Neurologii
Mikołów, Poland
Instytut Psychiatrii I Neurologii
KLINIKA NERWIC, ZABURZEŃ OSOBOWOŚCI I ODŻYWIANIA
Wilanów, Poland
Sponsor: Medical University Of Lodz
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.